Publications (20)63.37 Total impact
-
Article: Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs.
[show abstract] [hide abstract]
ABSTRACT: The pharmacokinetics of BAY 59-7939 - a novel, oral, direct Factor Xa inhibitor - were investigated in rats and dogs in support of preclinical safety studies and clinical development. BAY 59-7939 was rapidly absorbed after oral dosing, with an absolute bioavailability of 57-66% in rats, and 60-86% in dogs. Plasma pharmacokinetics of BAY 59-7939 were linear across the investigated dose range (1-10 mg kg(-1) in rats, 0.3-3 mg kg(-1) in dogs). Plasma clearance was low: 0.4 l kg(-1) h(-1) in rats and 0.3 l kg(-1) h(-1) in dogs; volume of distribution (V(ss)) was moderate: 0.3 l kg(-1) in rats, and 0.4 l kg(-1) in dogs. The elimination half-life after oral administration was short in both species (0.9-2.3 h). Whole-body autoradiography showed moderate tissue affinity. No retention or small volume enrichments of BAY 59-7939-related radioactivity were observed. The plasma-protein binding of BAY 59-7939 was high, species dependent and fully reversible. BAY 59-7939 was rapidly excreted in rats and dogs, and was not irreversibly retained. A dual mode of excretion (biliary/faecal and renal) was observed. In summary, BAY 59-7939 had a favourable, predictable pharmacokinetic profile, with high oral bioavailability and a dual route of excretion.Xenobiotica 10/2005; 35(9):891-910. · 1.79 Impact Factor -
Article: NO-independent regulatory site on soluble guanylate cyclase.
[show abstract] [hide abstract]
ABSTRACT: Nitric oxide (NO) is a widespread, potent, biological mediator that has many physiological and pathophysiological roles. Research in the field of NO appears to have followed a straightforward path, and the findings have been progressive: NO and cyclic GMP are involved in vasodilatation; glycerol trinitrate relaxes vascular smooth muscles by bioconversion to NO; mammalian cells synthesize NO; and last, NO mediates vasodilatation by stimulating the soluble guanylate cyclase (sGC), a heterodimeric (alpha/beta) haem protein that converts GTP to cGMP2-4. Here we report the discovery of a regulatory site on sGC. Using photoaffinity labelling, we have identified the cysteine 238 and cysteine 243 region in the alpha1-subunit of sGC as the target for a new type of sGC stimulator. Moreover, we present a pyrazolopyridine, BAY 41-2272, that potently stimulates sGC through this site by a mechanism that is independent of NO. This results in antiplatelet activity, a strong decrease in blood pressure and an increase in survival in a low-NO rat model of hypertension, and as such may offer an approach for treating cardiovascular diseases.Nature 04/2001; 410(6825):212-5. · 36.28 Impact Factor -
Article: NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272.
[show abstract] [hide abstract]
ABSTRACT: The most important receptor for nitric oxide is the soluble guanylate cyclase (sGC), a heme containing heterodimer. Recently, a pyrazolopyridine derivative BAY 41-2272, structurally related to YC-1, was identified stimulating soluble guanylate cyclase in an NO-independent manner, which results in vasodilatation and antiplatelet activity. The study described here addresses the identification of the NO-independent site on soluble guanylate cyclase. We developed a photoaffinity label (3H-meta-PAL) for the direct and NO-independent soluble guanylate cyclase (sGC) stimulator BAY 41-2272 by introducing an azido-group into the tritium labeled compound. The synthesized photoaffinitylabel directly stimulates the purified sGC and shows in combination with NO a synergistic effect on sGC activity. Irradiation with UV light of 3H-meta-PAL together with the highly purified sGC leads to a covalent binding to the alpha1-subunit of the enzyme. This binding is blocked by unlabeled meta-PAL, YC-1 and BAY 41-2272. For further identification of the NO-independent regulatory site the 3H-meta-PAL labeled sGC was fragmented by CNBr digest. The 3H-meta-PAL binds to a CNBr fragment, consisting of the amino acids 236-290 of the alpha1-subunit. Determination of radioactivity of the single PTH-cycles from the sequencing of this CNBr fragment detected the cysteines 238 and 243 as binding residues of the 3H-meta-PAL. Our data demonstrate that the region surrounding the cysteines 238 and 243 in the alpha1-subunit of the sGC could play an important role in regulation of sGC activity and could be the target of this new type of sGC stimulators.BMC Pharmacology 02/2001; 1:13. -
Article: Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats.
[show abstract] [hide abstract]
ABSTRACT: BAY 12-8039 (moxifloxacin-HCl) and 14C-labelled BAY 12-8039 were administered to male rats as single i.v. and oral doses of 4.6 and 5.0 mg/kg bodyweight respectively. The distribution of substance-associated radioactivity in the body was investigated by whole-body autoradiography. The concentrations of the unchanged compound in plasma, skin suction blister fluid and lung tissue were determined by HPLC. Whole-body autoradiography revealed distinctly higher concentrations of radioactivity in the gastrointestinal tract, urinary bladder and in most organs and tissues (e.g. kidneys, liver, spleen, lungs, various glands, cartilaginous tissues and in melanin-containing structures located in the eye, meninges and hair follicles of pigmented skin) than in blood. Radioactivity crossed the blood-brain barrier only to a small extent. The results show a high tissue affinity and a rapid and homogeneous distribution of radioactivity from blood to organs or tissues. No relevant difference in the distribution of radioactivity was found following i.v. and oral administration. After i.v. and oral dosing similar concentrations of the unchanged compound were determined in skin suction blister fluid and plasma. The concentrations of the unchanged compound in lung tissue were about three times higher than those in plasma following both i.v. and oral administration. The concentration-time courses for moxifloxacin in plasma and lung tissue were parallel.Journal of Antimicrobial Chemotherapy 06/1999; 43 Suppl B:61-7. · 5.07 Impact Factor -
Article: Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition.
[show abstract] [hide abstract]
ABSTRACT: Epidemiological studies have established that elevated concentrations of plasma cholesterol, particularly the low density lipoprotein (LDL) cholesterol, is one of the major risk factors for the development of arteriosclerosis and ischemic heart disease. Treatment with HMG-CoA reductase inhibitors (vastatins) has become the most successful drug treatment in lowering total plasma and LDL cholesterol concentrations in the last years. The vastatins already available for treatment are therapeutically used in a dose-range between 10 and 80 mg/day. The new enantiomerically pure pyridine derivative cerivastatin sodium has demonstrated its efficacy in significantly lower doses in the microgram-range, not only in preclinical but also in clinical studies with daily doses of only 0.1-0.3 mg. The differences in the therapeutic doses are reflected by the Ki- and IC50-values from enzyme inhibition tests in comparison with various HMG-CoA reductase inhibitors. Cerivastatin sodium exhibits much higher enzyme affinity with factors between 70 and almost 200. The Ki-value for cerivastatin sodium was 1.3 x 10(-9) M in comparison to 150 x 10(-9) M for lovastatin. The extremely high enzyme affinity of cerivastatin sodium was also reflected in its high activity in vivo. In acute in vivo studies cerivastatin sodium inhibited the hepatic [14C]cholesterol synthesis from [14C]acetate in both rats and dogs by 50% after oral administration at doses of 0.002 mg/kg body weight (ED50-values). This dose was comparable to 0.3 mg/kg of lovastatin. In subchronic dog studies a dose of 0.03 mg/kg lowered the serum LDL cholesterol concentration by 35% which is comparable with doses of 8-10 mg lovastatin/kg. Interesting results were observed in cholestyramine-primed dogs when 0.1 mg cerivastatin sodium/kg p.o. markedly decreased the serum triglycerides up to 70%. Cerivastatin shows a favourable pharmacokinetic profile with high liver selectivity. Rat studies have shown almost complete absorption and rapid hepatic clearance. Cerivastatin was highly bound to plasma proteins of rats, dogs and humans (>98%). Cerivastatin metabolites were excreted mainly via feces. The metabolism of cerivastatin sodium in man follows two metabolic pathways, demethylation to metabolite M1 and stereospecific hydroxylation to M23. The three major metabolites M1, M23 and the hydroxylated and demethylated metabolite M24 are highly active inhibitors not only in vitro but also in vivo. The human specific metabolites M23 and M24 inhibited the HMG-CoA reductase isolated from rat liver with the same potency as the parent compound cerivastatin sodium (IC50: 1.0-1.2 x 10(-9) M). M1 was slightly less active. Corresponding pharmacological activity was observed in vivo. M23 and M24 inhibited [14C]cholesterol synthesis from [14C]acetate in rat liver with ED50)-values between 0.001 and 0.002 mg/kg body weight which is similar to cerivastatin sodium and M1 exhibited an ED50-value of <0.006 mg/kg The strong inhibitory activity of these metabolites, in addition to cerivastatin's high enzyme affinity may explain the extraordinary pharmacological activity of cerivastatin and its ultra-low dose in man and demonstrates cerivastatin to be the most active HMG-CoA reductase inhibitor amongst all vastatins.Atherosclerosis 09/1998; 139 Suppl 1:S7-13. · 3.79 Impact Factor -
Article: Biotransformation of cerivastatin in mice, rats, and dogs in vivo.
[show abstract] [hide abstract]
ABSTRACT: Biotransformation of cerivastatin was investigated in mice, rats, and dogs in vivo using the 14C-labeled drug. Marked species differences exist, both in pathways and extent of cerivastatin metabolism. Unchanged drug, together with its lactone, predominates in dog plasma and represents 40% of the dose in the excreta, whereas in rat bile they account for approximately 10% of the dose. In mice, the drug is metabolized rapidly and almost completely. Biotransformation of cerivastatin occurs by three distinct phase I routes and by phase II conjugation with sugar-type moieties and taurine. Phase I routes are demethylation of the pyridinyl methyl ether, beta-oxidation of the 3,5-dihydroxy acid side chain, and reductive removal of the side chain 3-hydroxy group. In dogs, demethylation is the dominating phase I biotransformation. Phase II conjugation is equally important. In dog bile, different regioisomeric drug glucuronides and the benzylic glucuronide and glucoside conjugate of the demethylated drug were found. In rats, besides demethylation, beta-oxidation of the dihydroxy acid side chain-followed by reductive removal of the 5-hydroxy group-is the major reaction. The resulting pentenoic acid derivatives are observed in plasma and liver homogenate. These metabolites are subsequently conjugated with taurine and excreted in the bile. This metabolic sequence is also important in mice. Furthermore, only in mice, cerivastatin is subject to reductive removal of the 3-hydroxy group, together with demethylation. The 5-hydroxyheptenoic acids formed predominate in plasma and liver homogenate, whereas the corresponding taurine conjugates are excreted in the bile.Drug Metabolism and Disposition 08/1998; 26(7):640-52. · 3.73 Impact Factor -
Article: Carcinogen-induced Mitochondrial DNA Damage in the In Ovo Model.
[show abstract] [hide abstract]
ABSTRACT: After experimental exposure of turkey eggs in an in ovo model, the induction of preneoplastic liver lesions (Enzmann et al., 1992and 1995a) and alterations of the mitochondrial (mt) DNA of embryonic turkey livers (Enzmann et al., 1995b) could be demonstrated, showing the sensitivity and usefulness of this short-termed and inexpensive system for carcinogenicity testing. Chemically induced modification of mtDNA may be an important indicator of the carcinogenic potential of substances, as the mt genome may display a higher sensitivity to DNA damaging effects compared to nuclear DNA. To characterize mtDNA damages in ovo, application of diethylnitrosamine (DEN) was performed onto the chorioallantoic membrane (CAM) of the avian embryo. First, the distribution of a model substance after CAM application was measured by autoradiography. MtDNA damage after DEN exposure was demonstrated by gel electrophoresis of isolated mtDNA. Nitrosamine treatment induced a dose-dependent change of mtDNA conformation from supercoiled to relaxed shape, pointing to a possible induction of single-strand breaks.Toxicology in Vitro 06/1998; 12(3):329-33. · 2.78 Impact Factor -
Article: Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs.
[show abstract] [hide abstract]
ABSTRACT: The absorption, concentrations in plasma, metabolism and excretion of ramatroban ((+)-(3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid, CAS 116649-85-5, BAY u 3405) have been studied following a single intravenous, oral, or intraduodenal administration of 14C-labeled or nonlabeled compound to rats and dogs (dose range: 1-10 mg.kg-1). After intraduodenal administration of [14C]ramatroban, enteral absorption of radioactivity was rapid and almost complete both in bile duct-cannulated male rats (83%) and female dogs (95%). The oral bioavailability of ramatroban was complete in the dog but amounted to about 50% in the rat due to presystemic elimination. A marked food effect on the rate but not on the extent of absorption was observed in rats. The elimination of the parent compound from plasma occurred rapidly with total clearance of 1.2 l.h-1.kg-1 in male rats and 0.7 l.h-1.kg-1 in dogs. After oral administration to male rats AUC increased dose-proportionally between 1 and 10 mg.kg-1, whereas in Cmax an over-proportional increase was observed. Excretion of total radioactivity was fast and occurred predominantly via the biliary/fecal route in both species. The residues were low, 144 h after dosing less than 0.2% of the radioactivity remained in the body of rats. A considerable sex difference was found in rats following oral administration of ramatroban. In females a 3-fold higher AUC and a 1.7-fold longer half-life of unchanged compound, as well as 3-fold higher renal excretion of total radioactivity was observed. A marked species difference exists in the metabolism of ramatroban. In dogs the drug was almost exclusively metabolized via conjugation with glucuronic acid, whereas in rats oxidative phase I metabolism and glucuronidation were equally important. As a consequence enterohepatic circulation was much more pronounced in dogs (77%) than in rats (17% of the initial dose).Arzneimittel-Forschung 09/1997; 47(8):928-38. · 0.72 Impact Factor -
Article: Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 2nd communication: distribution to organs and tissues in male, female and pregnant rats, and characteristics of protein binding in plasma.
[show abstract] [hide abstract]
ABSTRACT: The distribution to organs and tissues, placental transfer and mammary excretion of ramatroban ((+)- (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid, CAS 116649-85-5, BAY u 3405) have been investigated in rats. Furthermore, the characteristics of protein binding in plasma of various species including man are described. After single oral administration of [14C]ramatroban to male rats, the radioactivity was preferentially localized in liver and kidneys, the tissue-to-plasma concentration ratios at tmax were 20 for liver and 6.3 for kidneys, respectively. For all other organs/tissues, a low to moderate affinity was detected. [14C]Ramatroban and its labeled metabolites did hardly penetrate the blood-brain barrier, and the brain-to-plasma concentration ratio was 0.03 at tmax. After repeated oral administration to male rats for 21 days, once daily, the radioactivity concentrations in organs and tissues showed only a slight tendency to accumulate. The AUC ratios in the dosing interval exhibited little or no increase, the highest accumulation factor was approximately 2. The steady-state of the trough levels in plasma was reached rapidly, with the third administration. The autoradiographic distribution pattern was not changed due to repeated administration. After receiving single oral doses of [14C]ramatroban, female rats showed almost identical autoradiographic distribution patterns of radioactivity compared with males. Although being similarly distributed, in most organs and tissues of pregnant rats (19th day of gestation) distinctly higher radioactivity concentrations were observed than in males. Maximal fetal concentrations occurred at 7 h after dosing. The distribution in fetuses was similar to that in maternal body, revealing relatively high concentrations in liver, kidneys, and gastrointestinal contents. The fetal AUC reached 68% of the AUC in maternal plasma. [14C]Ramatroban was excreted with the milk of lactating rats. The total amount within 24 h was estimated to be 1.7% of the maternal dose. [14C]Ramatroban is highly bound to plasma proteins in all species tested: rabbit (unbound fraction: 1.7-1.9%), rat (2.1-2.4%), man (2.0-2.7%), dog (2.4-2.8%), mouse (3.7-4.1%), guinea-pig (4.3-4.7%).Arzneimittel-Forschung 09/1997; 47(8):939-48. · 0.72 Impact Factor -
Article: Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.
[show abstract] [hide abstract]
ABSTRACT: The absorption, distribution, metabolism, and excretion of miglitol ((2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)-3,4,5-piperidinet riol, CAS 72432-03-2, BAY m 1099) have been studied following single and repeated administration of non-labelled and radiolabelled (3H, 14C) drug to rats, dogs, and human volunteers via different routes of administration (intravenous, oral, intraduodenal) and at various doses (0.3-450 mg/kg). After intravenous administration, miglitol is excreted rapidly and completely via the renal route. No indication was found for a metabolization of radiolabelled miglitol. The (renal) clearance of miglitol is in the range of the glomerular filtration rate. Miglitol is rapidly eliminated from plasma with apparent elimination half-lives of 0.4-1.8 h. Miglitol is virtually not bound to plasma proteins. After oral administration miglitol is rapidly and at low doses also completely absorbed. At higher doses (> or = 5 mg/kg in rats and dogs, > 50 mg in humans) a saturation of absorption becomes evident. Miglitol is distributed predominantly in the extracellular space. The volumes of distribution are low (0.3-0.8 l/ kg). In rats high concentrations were initially found in the kidneys, the blood and some well-perfused tissues. The permeation across the blood/brain barrier is very low. Elimination from organs and tissues occurs rapidly resulting in very low residual radioactivity in the body 2 days after dosing (< 0.9% of the dose). At this very low concentration level a terminal elimination phase of radioactivity characterized by half-lives of 50-110 h was observed giving rise to a slight tendency for accumulation (accumulation factors < 6) following repeated administration to rats. In pregnant rats [14C]miglitol crossed the placental barrier slowly and to a limited extent. In lactating rats miglitol was found in milk in concentrations similar to those in the maternal plasma.Arzneimittel-Forschung 07/1997; 47(6):734-45. · 0.72 Impact Factor -
Article: Autoradiographic localizatio of [125I]-C-ANP compared to [125I]-ANP in rat tissue
[show abstract] [hide abstract]
ABSTRACT: Whole-body autoradiography demonstrated the different distribution of [125I]-C-ANP and [125I]-ANP to rat tissues. Highest enrichment of radioactivity of both labelled peptides was found in the kidney. In some organs we found remarkable differences between [125I]-ANP and [125I]-C-ANP. In the kidney cortex, especially in the glomeruli, as well as in the endocardium, the zona glomerulosa and the medulla of the adrenal gland, where high levels of radioactivity after [125I]-ANP administration were detected, no or just few radioactivity was found after administration of [125I]-C-ANP. On the other hand in the kidney papilla and the outer subcortical medulla, characteristic blackening was found after [125I]-C-ANP administration. Those differences might be important for the understanding of pharmacological actions of ANP analogues.Histochemie 07/1991; 96(4):317-321. · 2.59 Impact Factor -
Article: Autoradiographic localization of 125I-big endothelin-1 in rat tissues.
[show abstract] [hide abstract]
ABSTRACT: Endothelin-1 (ET-1), a potent vasoconstrictor with a characteristically long-acting activity in vitro and in vivo, is thought to be generated in endothelial cells from a less active intermediate, big endothelin-1 (big ET-1). In addition to ET-1, big ET-1 is also present in the circulation. The autoradiographic localization of 125I-big ET-1 has been studied after intravenous administration in rat tissues. Highest enrichment of radioactivity was found in the kidney cortex. Compared to blood levels, enrichment of radioactivity is also detected, especially in the vascular wall of the aorta. Comparing the radioactivity pattern of ET-1 and big ET-1, a nearly identical tissue distribution is observed, with the exception of the relative enrichment in the lung, the endocardium and the zona glomerulosa.Arzneimittel-Forschung 06/1991; 41(5):478-80. · 0.72 Impact Factor -
Article: 125I-endothelin-1 and 125I-big endothelin-1 in rat tissues: autoradiographic localization and receptor binding.
[show abstract] [hide abstract]
ABSTRACT: The potent vasoconstrictor peptide, endothelin-1 (ET-1), which exhibits a characteristically long-acting activity in vitro and in vivo, is thought to be generated in endothelial cells from a less active intermediate, big endothelin-1 (big ET-1). In addition to ET-1, big ET-1 is also present in the circulation. The autoradiographic localization of 125I-big ET-1 and 125I-ET-1 has been studied after intravenous administration in rat tissues. Highest enrichment of radioactivity was found in the kidney cortex for both peptides. Compared to blood levels, enrichment of radioactivity is also detected, in the vascular wall of the aorta. Comparing the radioactivity pattern of ET-1 and big ET-1, a nearly identical tissue distribution is observed, with the exception of the relative enrichment in the lung and the zona glomerulosa after administration of ET-1. Both radioligands show a specific and saturable binding to lung and kidney membranes. In the case of lung tissue, Ki values are 10(-10) M for endothelin-1 and 10(-8) M for big endothelin-1. This difference in affinities may account for the lack of binding of big endothelin-1 to lung tissue.Histochemistry 02/1991; 95(6):621-8. -
Article: Autoradiographic localization of [125I]-C-ANP compared to [125I]-ANP in rat tissue.
[show abstract] [hide abstract]
ABSTRACT: Whole-body autoradiography demonstrated the different distribution of [125I]-C-ANP and [125I]-ANP to rat tissues. Highest enrichment of radioactivity of both labelled peptides was found in the kidney. In some organs we found remarkable differences between [125I]-ANP and [125I]-C-ANP. In the kidney cortex, especially in the glomeruli, as well as in the endocardium, the zona glomerulosa and the medulla of the adrenal gland, where high levels of radioactivity after [125I]-ANP administration were detected, no or just few radioactivity was found after administration of [125I]-C-ANP. On the other hand in the kidney papilla and the outer subcortical medulla, characteristic blackening was found after [125I]-C-ANP administration. Those differences might be important for the understanding of pharmacological actions of ANP analogues.Histochemistry 02/1991; 96(4):317-21. -
Article: Pharmacokinetics of acarbose. Part II: Distribution to and elimination from tissues and organs following single or repeated administration of [14C]acarbose to rats and dogs.
[show abstract] [hide abstract]
ABSTRACT: Acarbose (O-4,6-dideoxy-4-[[1S,4R,5S,6S)-4,5,6-trihydroxy-3- (hydroxymethyl)-2-cyclohexen-1-yl]amino]-alpha-D-glucopyranosyl- (1----4)-O-alpha-D-glucopyranosyl-(1----4)-D-glucopyranose, Bay g 5421) labelled with 14C was administered to male rats, pregnant and lactating rats as well as to female dogs with single intravenous or oral doses (2 or 4 mg.kg-1) and with repeated oral doses of 2 mg.kg-1 to male rats for 3 weeks. The distribution of radioactivity to organs and tissues, the placental transfer and the secretion into milk was studied using whole-body autoradiographic methods and/or quantitative determination of total radioactivity after autopsy. Unchanged [14C]acarbose was distributed predominantly in the extracellular space, as observed after intravenous dosing to rats. According to the main excretion route, high concentrations were found in kidneys and urine and additionally in blood, lung, and connective tissue or interstitial space. The permeability of the blood/brain barrier for [14C]acarbose and/or its metabolites was very low. No indication was found for distinct differences in the distribution patterns in rats and dogs after intravenous and also in dogs after oral administration. In contrast, in rats after oral dosing the distribution pattern of radioactivity was different with relatively high concentrations in liver, kidney, adrenal gland, spleen, and intestinal mucosa. Due to the slow absorption of the microbial degradation products of [14C]acarbose from the intestine maximum concentrations in the different tissues were reached 8-24 h after dosing.(ABSTRACT TRUNCATED AT 250 WORDS)Arzneimittel-Forschung 11/1989; 39(10):1261-7. · 0.72 Impact Factor -
Article: Autoradiographic localization of [125I]endothelin-1 and [125I]atrial natriuretic peptide in rat tissue: a comparative study.
[show abstract] [hide abstract]
ABSTRACT: The autoradiographic localization of [125I]endothelin-1 (ET-1) and [125I]atrial natriuretic peptide (ANP) after i.v. administration has been investigated in rats. Labeled peptides are rapidly distributed to tissues and peripheral organs. After administration of [125I]ET-1 (1-21), the highest enrichment of radioactivity was found in the lung, kidney, liver, adrenal gland, and heart. After administration of [125I]ANP (1-28), the highest levels of radioactivity could be observed in the kidney, adrenal gland, and endocardium. Compared to blood levels in both cases, a relative enrichment of radioactivity is also found in the vascular wall of the aorta. For ANP, no distribution of radioactivity in the lung could be observed. Other organs, especially the kidney and the adrenal gland, showed a similar distribution pattern with respect to substructures.Journal of Cardiovascular Pharmacology 02/1989; 13 Suppl 5:S67-73; discussion S74. · 2.29 Impact Factor -
Article: Pharmacokinetics of rioprostil in rats.
[show abstract] [hide abstract]
ABSTRACT: The pharmacokinetics of rioprostil in rats has been investigated following a single intravenous or oral dose of rioprostil between 0.004 and 10 mg/kg. Rioprostil is eliminated from plasma following an intravenous dose rapidly (t1/2 = 0.22 h) and nearly exclusively by biotransformation. The high total clearance (CL = 5.4 l.h-1.kg-1) indicates an additional extrahepatic metabolism. A systemic bioavailability of 2%, in spite of a rapid and nearly complete absorption (fa = 90%), indicates an extended first-pass effect. Twenty-four hours after the administration of [3H]rioprostil the residual radioactivity in the animal amounted to less than 1% of the dose administered.Scandinavian journal of gastroenterology. Supplement 02/1989; 164:46-50; discussion 50-1. -
Article: Autoradiographic localization of 125J-endothelin in rat tissues.
[show abstract] [hide abstract]
ABSTRACT: A potent peptidergic vasoconstrictor in vitro and in vivo termed endothelin has been isolated from the supernatant of cultured endothelial cells. The autoradiographic localization of 125J-endothelin has been studied after intravenous administration in rat tissues. Highest enrichment of radioactivity was found in kidney and lung. Activity was also detected, especially in vascular wall of the aorta and adrenal gland.Arzneimittel-Forschung 02/1989; 39(1):59-61. · 0.72 Impact Factor -
Article: The pharmacokinetics of nitrendipine. II. Distribution to and elimination from organs and tissues of rats and dogs after single or repeated administration of [14C]nitrendipine.
[show abstract] [hide abstract]
ABSTRACT: [14C]nitrendipine (3-ethyl 5-methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine dicarboxylate, Bay e 5009, Baypress, Bayotensin) was administered to male rats, pregnant and lactating female rats, and female dogs intravenously or orally once as well as to male rats repeatedly over a period of 4 weeks (rat 5 (and 10) mg/kg, dog approximately 3 mg/kg). The distribution of radioactivity (unchanged compound and metabolites) was investigated using whole-body autoradiography as well as quantitative measurements of the organ and tissue concentrations of radioactivity after necropsy. [14C]nitrendipine was distributed rapidly and heterogeneously into the organs and tissues of rats. Already 24 h after administration most of the radioactivity had reached the gastro-intestinal (GI) tract via biliary secretion. High concentrations were also detectable in liver and kidneys. The radioactivity was eliminated from the tissues with terminal half-lives lying between 52 (plasma) and 360 h (muscle). Only 0.13% of the administered radioactivity was detectable in the body (excl. GI-tract) after 10 days. In dogs, the distribution pattern was similar to that observed in rats. After 28 daily administrations of [14C]nitrendipine to male rats the plasma and tissue equivalent concentrations were 3 (plasma) to 12 times (adipose tissue) higher than after single administration. The half-lives were increased by 20 to 70%, lying between 2 and 15 days. There were no indications for any specific retention of the radioactivity. The radioactivity from [14C]nitrendipine was secreted into the milk of lactating rats and crossed the placental barrier.(ABSTRACT TRUNCATED AT 250 WORDS)Arzneimittel-Forschung 12/1988; 38(11):1599-604. · 0.72 Impact Factor -
Article: Carcinogen-induced Mitochondrial DNA Damage in the In Ovo Model
[show abstract] [hide abstract]
ABSTRACT: After experimental exposure of turkey eggs in an in ovo model, the induction of preneoplastic liver lesions (Enzmann et al., 1992and 1995a) and alterations of the mitochondrial (mt) DNA of embryonic turkey livers (Enzmann et al., 1995b) could be demonstrated, showing the sensitivity and usefulness of this short-termed and inexpensive system for carcinogenicity testing. Chemically induced modification of mtDNA may be an important indicator of the carcinogenic potential of substances, as the mt genome may display a higher sensitivity to DNA damaging effects compared to nuclear DNA. To characterize mtDNA damages in ovo, application of diethylnitrosamine (DEN) was performed onto the chorioallantoic membrane (CAM) of the avian embryo. First, the distribution of a model substance after CAM application was measured by autoradiography. MtDNA damage after DEN exposure was demonstrated by gel electrophoresis of isolated mtDNA. Nitrosamine treatment induced a dose-dependent change of mtDNA conformation from supercoiled to relaxed shape, pointing to a possible induction of single-strand breaks.Toxicology in Vitro.
Top co-authors
Top Journals
- Arzneimittel-Forschung (7)
- Histochemistry (2)
- Atherosclerosis (1)
- Nature (1)
- Xenobiotica (1)
Institutions
-
1997
-
Bayer Pharma AG
Berlin, Land Berlin, Germany
-
